Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | FPR1 | P21462 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.37 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.36 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6657498 | 0.90 | CXCR4 (0.46) | CXCR4ALDH1A1L3MBTL1KDM4ELMNA | |
| SCHEMBL6656540 | 0.88 | CXCR4 (0.52) | CXCR4LMNAHDAC3HDAC1HDAC2 | |
| SCHEMBL6657911 | 0.84 | CXCR4 (0.51) | CXCR4LMNAHDAC3HDAC1HDAC2 | |
| SCHEMBL6651943 | 0.84 | CXCR4 (0.51) | CXCR4LMNAHDAC3HDAC1HDAC2 | |
| SCHEMBL6652415 | 0.82 | CXCR4 (0.49) | CXCR4LMNAHDAC3HDAC1HDAC2 | |
| SCHEMBL6653967 | 0.81 | CXCR4 (0.58) | CXCR4LMNAHDAC3HDAC1HDAC2 | |
| SCHEMBL6653460 | 0.81 | CXCR4 (0.54) | CXCR4HDAC3HDAC1HDAC2CASR | |
| SCHEMBL6655575 | 0.80 | CXCR4 (0.58) | CXCR4HDAC3HDAC1HDAC2CASR | |
| SCHEMBL6656486 | 0.79 | CXCR4 (0.74) | CXCR4ALDH1A1LMNACASRMETAP2 | |
| SCHEMBL6653528 | 0.79 | CXCR4 (0.52) | CXCR4HDAC1GPR139CASRMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | KUREHA CORPORATION (JP) | 2004-12-16 | — | — | US | claimed |
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | KUREHA CORPORATION (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1431290-A1 | NOVEL NITROGENOUS COMPOUND AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254221-A1 | Novel Nitrogenous Compound and use thereof | NGLY1, NOD1, CCR1 | CXCR4 88/4885ALDH1A1 1497/4885L3MBTL1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.